Is NVCT or CLDX more profitable?

Celldex Therapeutics' return on equity of -52.35% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -184.25% -105.24% Celldex Therapeutics N/A -52.35% -47.61%

Does the media refer more to NVCT or CLDX?

In the previous week, Celldex Therapeutics had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Celldex Therapeutics and 2 mentions for Nuvectis Pharma. Celldex Therapeutics' average media sentiment score of 0.76 beat Nuvectis Pharma's score of 0.08 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Celldex Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NVCT or QURE more profitable?

Nuvectis Pharma has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. uniQure's return on equity of -111.96% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Nuvectis Pharma N/A -184.25% -105.24% uniQure -1,350.73% -111.96% -29.01%

Does the media favor NVCT or QURE?

In the previous week, Nuvectis Pharma had 1 more articles in the media than uniQure. MarketBeat recorded 2 mentions for Nuvectis Pharma and 1 mentions for uniQure. uniQure's average media sentiment score of 1.56 beat Nuvectis Pharma's score of 0.08 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvectis Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral uniQure 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer BEAM or NVCT?

In the previous week, Beam Therapeutics had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Beam Therapeutics and 2 mentions for Nuvectis Pharma. Beam Therapeutics' average media sentiment score of 0.50 beat Nuvectis Pharma's score of 0.08 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvectis Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMNM or NVCT more profitable?

Immunome's return on equity of -50.56% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Immunome N/A -50.56% -46.93% Nuvectis Pharma N/A -184.25% -105.24%

Does the media prefer IMNM or NVCT?

In the previous week, Immunome had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 4 mentions for Immunome and 2 mentions for Nuvectis Pharma. Immunome's average media sentiment score of 0.60 beat Nuvectis Pharma's score of 0.08 indicating that Immunome is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer NAMS or NVCT?

In the previous week, NewAmsterdam Pharma had 6 more articles in the media than Nuvectis Pharma. MarketBeat recorded 8 mentions for NewAmsterdam Pharma and 2 mentions for Nuvectis Pharma. NewAmsterdam Pharma's average media sentiment score of 0.82 beat Nuvectis Pharma's score of 0.08 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Nuvectis Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Nuvectis Pharma (NVCT) Competitors

$22.00 +0.62 (+2.90%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$22.15 +0.15 (+0.66%)

As of 09/18/2026 07:44 PM Eastern

Compare

NVCT vs. CLDX, QURE, BEAM, IMNM, and NAMS

Should you buy Nuvectis Pharma stock or one of its competitors? Nuvectis Pharma's main competitors and comparable companies include Celldex Therapeutics (CLDX), uniQure (QURE), Beam Therapeutics (BEAM), Immunome (IMNM), and NewAmsterdam Pharma (NAMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nuvectis Pharma compare to Celldex Therapeutics?

Nuvectis Pharma (NASDAQ:NVCT) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

Nuvectis Pharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Nuvectis Pharma currently has a consensus target price of $36.25, indicating a potential upside of 64.77%. Celldex Therapeutics has a consensus target price of $56.42, indicating a potential upside of 47.53%. Given Nuvectis Pharma's higher probable upside, research analysts clearly believe Nuvectis Pharma is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Nuvectis Pharma has higher earnings, but lower revenue than Celldex Therapeutics. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
Celldex Therapeutics	$1.54M	1,949.99	-$258.76M	-$4.35	N/A

Celldex Therapeutics' return on equity of -52.35% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
Celldex Therapeutics	N/A	-52.35%	-47.61%

In the previous week, Celldex Therapeutics had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Celldex Therapeutics and 2 mentions for Nuvectis Pharma. Celldex Therapeutics' average media sentiment score of 0.76 beat Nuvectis Pharma's score of 0.08 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celldex Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.8% of Nuvectis Pharma shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Celldex Therapeutics beats Nuvectis Pharma on 9 of the 14 factors compared between the two stocks.

How does Nuvectis Pharma compare to uniQure?

Nuvectis Pharma (NASDAQ:NVCT) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Nuvectis Pharma has higher earnings, but lower revenue than uniQure. Nuvectis Pharma is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A
uniQure	$16.10M	189.58	-$198.97M	-$4.01	N/A

Nuvectis Pharma has a beta of -0.26, suggesting that its share price is 126% less volatile than the broader market. Comparatively, uniQure has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Nuvectis Pharma presently has a consensus price target of $36.25, indicating a potential upside of 64.77%. uniQure has a consensus price target of $65.00, indicating a potential upside of 47.73%. Given Nuvectis Pharma's stronger consensus rating and higher possible upside, research analysts clearly believe Nuvectis Pharma is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
uniQure	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 28.6% of Nuvectis Pharma shares are owned by company insiders. Comparatively, 4.7% of uniQure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nuvectis Pharma has a net margin of 0.00% compared to uniQure's net margin of -1,350.73%. uniQure's return on equity of -111.96% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvectis Pharma	N/A	-184.25%	-105.24%
uniQure	-1,350.73%	-111.96%	-29.01%

In the previous week, Nuvectis Pharma had 1 more articles in the media than uniQure. MarketBeat recorded 2 mentions for Nuvectis Pharma and 1 mentions for uniQure. uniQure's average media sentiment score of 1.56 beat Nuvectis Pharma's score of 0.08 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvectis Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Nuvectis Pharma beats uniQure on 9 of the 16 factors compared between the two stocks.

How does Nuvectis Pharma compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Nuvectis Pharma (NASDAQ:NVCT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Beam Therapeutics has a beta of 2.22, indicating that its stock price is 122% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.26, indicating that its stock price is 126% less volatile than the broader market.

Nuvectis Pharma has a net margin of 0.00% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Nuvectis Pharma	N/A	-184.25%	-105.24%

In the previous week, Beam Therapeutics had 3 more articles in the media than Nuvectis Pharma. MarketBeat recorded 5 mentions for Beam Therapeutics and 2 mentions for Nuvectis Pharma. Beam Therapeutics' average media sentiment score of 0.50 beat Nuvectis Pharma's score of 0.08 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvectis Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Nuvectis Pharma has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Nuvectis Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	18.44	-$79.99M	-$0.86	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Beam Therapeutics presently has a consensus target price of $49.00, indicating a potential upside of 96.39%. Nuvectis Pharma has a consensus target price of $36.25, indicating a potential upside of 64.77%. Given Beam Therapeutics' higher probable upside, equities research analysts clearly believe Beam Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Beam Therapeutics beats Nuvectis Pharma on 10 of the 16 factors compared between the two stocks.

How does Nuvectis Pharma compare to Immunome?

Immunome (NASDAQ:IMNM) and Nuvectis Pharma (NASDAQ:NVCT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

Nuvectis Pharma has lower revenue, but higher earnings than Immunome. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	392.29	-$212.39M	-$2.53	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Immunome has a beta of 2.13, indicating that its share price is 113% more volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.26, indicating that its share price is 126% less volatile than the broader market.

44.6% of Immunome shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 28.6% of Nuvectis Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Immunome had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 4 mentions for Immunome and 2 mentions for Nuvectis Pharma. Immunome's average media sentiment score of 0.60 beat Nuvectis Pharma's score of 0.08 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvectis Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunome currently has a consensus price target of $34.64, indicating a potential upside of 44.50%. Nuvectis Pharma has a consensus price target of $36.25, indicating a potential upside of 64.77%. Given Nuvectis Pharma's higher probable upside, analysts plainly believe Nuvectis Pharma is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Immunome's return on equity of -50.56% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
Nuvectis Pharma	N/A	-184.25%	-105.24%

Summary

Immunome beats Nuvectis Pharma on 9 of the 15 factors compared between the two stocks.

How does Nuvectis Pharma compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Nuvectis Pharma (NASDAQ:NVCT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

In the previous week, NewAmsterdam Pharma had 6 more articles in the media than Nuvectis Pharma. MarketBeat recorded 8 mentions for NewAmsterdam Pharma and 2 mentions for Nuvectis Pharma. NewAmsterdam Pharma's average media sentiment score of 0.82 beat Nuvectis Pharma's score of 0.08 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvectis Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 28.6% of Nuvectis Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

NewAmsterdam Pharma has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.26, suggesting that its stock price is 126% less volatile than the broader market.

Nuvectis Pharma has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%
Nuvectis Pharma	N/A	-184.25%	-105.24%

Nuvectis Pharma has lower revenue, but higher earnings than NewAmsterdam Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	119.49	-$203.82M	-$2.16	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

NewAmsterdam Pharma currently has a consensus target price of $49.73, indicating a potential upside of 121.11%. Nuvectis Pharma has a consensus target price of $36.25, indicating a potential upside of 64.77%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe NewAmsterdam Pharma is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

NewAmsterdam Pharma beats Nuvectis Pharma on 10 of the 15 factors compared between the two stocks.

Get Nuvectis Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVCT vs. The Competition

Export

Metric	Nuvectis Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$718.17M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-16.79	14.23	274.93	25.38
Price / Sales	N/A	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	30.56	15.45	10.46	6.33
Net Income	-$26.44M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-8.30%	-1.21%	0.59%	1.12%
1 Month Performance	-5.78%	-3.29%	-1.74%	-2.39%
1 Year Performance	250.88%	37.74%	18.13%	5.35%

Nuvectis Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVCT Nuvectis Pharma	3.6506 of 5 stars	$22.00 +2.9%	$36.25 +64.8%	+250.9%	$718.17M	N/A	N/A	13	Gap Down High Trading Volume
CLDX Celldex Therapeutics	2.118 of 5 stars	$39.12 -1.4%	$56.08 +43.4%	+55.4%	$3.12B	$158K	N/A	150	News Coverage
QURE uniQure	3.6861 of 5 stars	$45.68 +2.7%	$65.00 +42.3%	+217.2%	$3.09B	$16.10M	N/A	500	Positive News
BEAM Beam Therapeutics	2.2337 of 5 stars	$26.83 -9.5%	$49.00 +82.6%	+2.6%	$3.06B	$139.74M	N/A	510	High Trading Volume
IMNM Immunome	2.8679 of 5 stars	$26.81 +0.2%	$34.64 +29.2%	+155.3%	$3.04B	N/A	N/A	40	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVCT) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvectis Pharma (NVCT) Competitors

NVCT vs. CLDX, QURE, BEAM, IMNM, and NAMS

How does Nuvectis Pharma compare to Celldex Therapeutics?

Summary

How does Nuvectis Pharma compare to uniQure?

Summary

How does Nuvectis Pharma compare to Beam Therapeutics?

Summary

How does Nuvectis Pharma compare to Immunome?

Summary

How does Nuvectis Pharma compare to NewAmsterdam Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvectis Pharma (NVCT) Competitors

NVCT vs. CLDX, QURE, BEAM, IMNM, and NAMS

How does Nuvectis Pharma compare to Celldex Therapeutics?

Which has more volatility and risk, NVCT or CLDX?

Do analysts prefer NVCT or CLDX?

Which has stronger valuation & earnings, NVCT or CLDX?

Is NVCT or CLDX more profitable?

Does the media refer more to NVCT or CLDX?

Do insiders & institutionals believe in NVCT or CLDX?

Summary

How does Nuvectis Pharma compare to uniQure?

Which has stronger earnings & valuation, NVCT or QURE?

Which has more risk and volatility, NVCT or QURE?

Do analysts recommend NVCT or QURE?

Do insiders and institutionals believe in NVCT or QURE?

Is NVCT or QURE more profitable?

Does the media favor NVCT or QURE?

Summary

How does Nuvectis Pharma compare to Beam Therapeutics?

Which has more volatility and risk, BEAM or NVCT?

Is BEAM or NVCT more profitable?

Does the media prefer BEAM or NVCT?

Do institutionals & insiders believe in BEAM or NVCT?

Which has preferable earnings and valuation, BEAM or NVCT?

Do analysts recommend BEAM or NVCT?

Summary

How does Nuvectis Pharma compare to Immunome?

Which has stronger valuation and earnings, IMNM or NVCT?

Which has more volatility & risk, IMNM or NVCT?

Do institutionals and insiders believe in IMNM or NVCT?

Does the media prefer IMNM or NVCT?

Do analysts recommend IMNM or NVCT?

Is IMNM or NVCT more profitable?

Summary

How does Nuvectis Pharma compare to NewAmsterdam Pharma?

Does the media prefer NAMS or NVCT?

Do institutionals & insiders believe in NAMS or NVCT?

Which has more risk & volatility, NAMS or NVCT?

Is NAMS or NVCT more profitable?

Which has stronger earnings and valuation, NAMS or NVCT?

Do analysts rate NAMS or NVCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT vs. The Competition

Nuvectis Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools